In the survival analysis of 41 patients with HER2 amplified CRC, lymphovascular invasion (p = 0.015), lymph node metastasis (p = 0.018), and pathologic AJCC stage III/IV (p = 0.014) were statistically associated with shorter OS. Here, ERBB2 is linked to metastatic malignant neoplasm in the lymph nodes.